Defactinib
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 129 publications
Current perspectives in the pharmacological combination treatment for low-grade serous ovarian cancer.
Journal: Expert opinion on pharmacotherapy
Published: October 16, 2026
FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer.
Journal: Science translational medicine
Published: September 30, 2026
Progress with FAK inhibitors in the patent literature (2020-present).
Journal: Expert opinion on therapeutic patents
Published: September 18, 2026
Low-grade serous ovarian cancer: 2026 expert consensus report.
Journal: Gynecologic oncology
Published: September 09, 2026
RAF/MEK clamp inhibition with avutometinib and cetuximab in RAF1 S257L-mutated, anti-EGFR-refractory metastatic colorectal cancer in Gaucher's disease.
Journal: The oncologist
Published: July 08, 2026
Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.
Journal: Gynecologic oncology
Published: June 15, 2026
Corrigendum to 'Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer' [International Journal of Gynecological Cancer Volume 36 Issue 5 (2026) 104635].
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 12, 2026
Scaffold hopping-directed design and discovery of N1-substituted aminopyrimidine-indole derivatives as FAK inhibitors with anti-pancreatic cancer activity.
Journal: Bioorganic & medicinal chemistry
Published: June 01, 2026
An evaluation of avutometinib in combination with defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.
Journal: Expert review of anticancer therapy
Published: April 30, 2026
Simultaneous Estimation of Avutometinib and Defactinib in Rat Plasma by Using LC-MS/MS and Its Application to Pharmacokinetic Studies.
Journal: Biomedical chromatography : BMC
Published: April 29, 2026
Vitronectin enrichment in prostate cancer liver metastases promotes adhesion and survival.
Journal: Cancer research communications
Published: April 24, 2026
Last Updated: 11/08/2026